$18.60
-0.33-1.74%
最終更新: Oct 16, 4:00 PM
$18.89
-0.04-0.21%
Benzinga
Benzinga
Benzinga
金曜日, 10 16
Benzinga
© 2026 Benzinga | All Rights Reserved
Nuvectis Pharma (NVCT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.26 | $-0.31 | $-0.28 | $-0.24 |
| Actual | $-0.30 | $-0.26 | $-0.31 | $-0.44 |
| Surprise | -15.4% | +16.1% | -10.7% | -83.3% |
| Revenue | ||||
| Estimate | — | — | — | — |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | — | — | — | — |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.24 | $-0.25 |
| Revenue | ||
| Consensus | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $-0.30 | $-0.26 | -15.4 % |
| Q1 | May 5, 2026 | $-0.26 | $-0.31 | 16.1 % |
| Q4 | Feb 11, 2026 | $-0.31 | $-0.28 | -10.7 % |
| Q3 | Nov 4, 2025 | $-0.44 | $-0.24 | -83.3 % |